RealEC Technologies(TM), the industry's leading secure B2B eCommerce exchange for mortgage fulfillment transactions and majority-owned subsidiary
of FNIS, has successfully processed 1.
During the first quarter of fiscal 2007, the Company's primary focus was the initiation of the phase 3 clinical trial for SinuNase[TM], a potential blockbuster intranasal Amphotericin B formulation for Chronic Sinusitis (CS); and, through its majority-owned subsidiary
, Biovest International, Inc.
Arrowhead Research Corporation (NASDAQ:ARWR) announced today that its majority-owned subsidiary
, Unidym, Inc.
TerreStar"), a majority-owned subsidiary
of Motient Corporation ("Motient") (MNCP), announced today that it intends to offer Senior Secured Discount Notes due 2015 for expected aggregate gross proceeds of $450.
com), a majority-owned subsidiary
of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize delivery-enhanced small-molecule therapeutics and nucleic acids.
Through Accentia's majority-owned subsidiary
, Biovest International, significant advances have been made in the development of BiovaxID, a personalized biologic therapeutic vaccine for follicular non-Hodgkin's lymphoma, in particular:
a leading developer of mainframe connectivity, channel gateway, storage and data distribution products, announced today that its Channel Gateway 3200 mainframe distribution encryption solution is in full production at Fidelity Information Services, a majority-owned subsidiary
of Fidelity National Financial, Inc.
Biovest is a majority-owned subsidiary
of Accentia Biopharmaceuticals, Inc.
Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary
of Arrowhead Research Corporation (NASDAQ:ARWR), announced results of a pilot safety-study using Calando's lead siRNA therapeutic candidate in non-human primates.
Arrowhead Research Corporation (NASDAQ:ARWR), announced today that Edward Jacobs will be appointed Chief Executive Officer & President of its majority-owned subsidiary
, Insert Therapeutics, on January 1, 2007.
a majority-owned subsidiary
of Arrowhead, will present at the Second Annual Meeting of the Oligonucleotide Therapeutic Society on Friday, October 20, 2006 at 5:00 p.
which is a majority-owned subsidiary
of Barclays Bank PLC, none of which is affiliated with SEI.